Piramal Pharma Limited said it would acquire the remaining 26 per cent equity stake in Yapan Bio Private Limited, a subsidiary of the company, from its existing shareholders.
The administrative committee authorised by Piramal Pharma’s board of directors has “approved the exercise of the company’s call option to acquire the balance 26 per cent equity stake in Yapan Bio Private Limited,” the drugmaker said in an announcement to the stock exchange.
The final terms of the acquisition, including the acquisition consideration and the effective date of transfer of shares, are yet to be finalised, it added.
“Consequent to the exercise of the call option, the company is engaged in discussions with the shareholders of Yapan in relation to matters necessary for consummation of the proposed transaction,” it said.
Yapan is a contract development and manufacturing organisation focused on services for vaccines and biologics. After the proposed transaction is completed, Piramal Pharma’s shareholding in Yapan is expected to increase from the present 74 per cent to 100 per cent, making it a wholly owned subsidiary, it said.
Published on November 19, 2026




